Reset Therapeutics
Biopharmaceutical firm, Reset Therapeutics, innovates modulation therapies for the human circadian system.
- 30
- Series B
Reset Therapeutics, founded with a mission to revolutionize biopharmaceutical treatments, focuses on developing and commercializing therapies that modulate the human circadian system. Their innovative products aim to address various health conditions by targeting the body's internal clock, offering potential solutions for disorders related to sleep, metabolism, and other circadian rhythm-related issues.
Notable figures in the company include leading scientists and industry experts dedicated to advancing circadian modulation therapies. Reset Therapeutics has garnered attention from prominent investors in the biotech sector, reflecting confidence in their groundbreaking approach. Their achievements in preclinical and clinical trials underscore their impact on the biopharmaceutical landscape, positioning them as pioneers in circadian system modulation.
Similar Companies

Reset Pharmaceuticals
resetpharma.com
Synchronicity Pharma

Rheos Medicines
rheosrx.com
Nativis
nativis.com

Circadian Positioning Systems
sleepcps.com
Thesan Pharmaceuticals
thesanpharma.com

PIN Pharma
pinpharma.com

Halia Therapeutics
haliatx.com

Akttyva Therapeutics
akttyva.com

Theracos
theracos.com

Rectify Pharmaceuticals
rectifypharma.com

Epicrispr Biotechnologies
epicrispr.com

Juventas Therapeutics
juventasinc.com
Somnus Therapeutics
somnusthera.com

Fuse Biotherapeutics
fusebiotx.com
Quick Facts
Who are Reset Therapeutics' competitors?
Companies similar to Reset Therapeutics include Reset Pharmaceuticals, Synchronicity Pharma, Rheos Medicines and Nativis.
When was Reset Therapeutics founded?
Reset Therapeutics was founded in 2008.
Where is Reset Therapeutics' headquarters located?
Reset Therapeutics' headquarters is located in South San Francisco, CA, US.
When was Reset Therapeutics' last funding round?
Reset Therapeutics' most recent funding round was for $29.7M (USD) in February 2016.
How much disclosed funding has Reset Therapeutics raised?
As of Feb 19, 2016, Reset Therapeutics has disclosed funding of $53.6M (USD). Undisclosed round amounts are excluded.
How many employees does Reset Therapeutics have?
Reset Therapeutics has 30 employees as of Feb 4, 2024.
Classification
- Ownership
- Technology
- Geographic Exposure
- Customer
- Main Product
- NAICS
- 540000Professional, Scientific, and Technical Services
- 541714Research and Development in Biotechnology (except Nanobiotechnology)
- 541000Professional, Scientific, and Technical Services
- 541700Scientific Research and Development Services
- 541710Research and Development in the Physical, Engineering, and Life Sciences
- SIC
- 8700Engineering, Accounting, Research, Management, And Related Services
- 8730Research, Development, And Testing Services
- 8731Commercial Physical and Biological Research
Show 13 more industry codes
- NAICS
- 320000Manufacturing
- 325400Pharmaceutical and Medicine Manufacturing
- 620000Health Care and Social Assistance
- 325000Chemical Manufacturing
- 623000Nursing and Residential Care Facilities
- 325410Pharmaceutical and Medicine Manufacturing
- 325412Pharmaceutical Preparation Manufacturing
- SIC
- 2800Chemicals And Allied Products
- 8000Health Services
- 2830Drugs
- 8040Offices And Clinics Of Other Health Practitioners
- 2834Pharmaceutical Preparations
- 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified